Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hereditary Angioedema: full-pipeline trial registry
2 of 15 indexed Hereditary Angioedema trials are currently recruiting.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 2 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Hereditary Angioedema: 15 US clinical trials tracked, 2 recruiting.
Hereditary Angioedema is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Shire, running 4 of these trials.
Enrollment posture brief
Registry condition hereditary-angioedema
OPEN 2 | RECR 13% | LATE 9 | EARLY 6 | RANK #1140 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Drug Addiction (13% recruiting · 15 trials)
Hereditary Angioedema lists 2 open slots (13% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hereditary Angioedema on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hereditary Angioedema is recruiting below its size-band peers.
2 of 15 indexed trials (13.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Hereditary Angioedema research.
Shire accounts for 4 of 15 trials (26.7%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most Hereditary Angioedema trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 15 trials that report a genuine target (sentinel values excluded). 12 of those (80%) plan for fewer than 100 participants.
-
Hereditary Angioedema research is mostly interventional.
15 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
ADARx Pharmaceuticals
NCT06960213
Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab
CSL Behring
NCT06806657
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
Ionis Pharmaceuticals
NCT05392114
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
KalVista Pharmaceuticals
NCT05505916
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
Intellia Therapeutics
NCT06634420
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
Astria Therapeutics
NCT06007677
A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema
BioMarin Pharmaceutical
NCT05121376
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
KalVista Pharmaceuticals
NCT05511922
Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks
Shire
NCT00462709
OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)
Ionis Pharmaceuticals
NCT05139810
A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II
KalVista Pharmaceuticals
NCT04208412
C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks
Shire
NCT00289211
A Study of STAR-0215 in Participants With Hereditary Angioedema
Astria Therapeutics
NCT05695248
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration
Shire
NCT01095497
A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase
Shire
NCT01426763
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 4 |
| Phase 3 | 8 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Hereditary Angioedema records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hereditary Angioedema trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hereditary Angioedema page
15 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Hereditary Angioedema trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Shire sponsors the most Hereditary Angioedema trials on record, review their full trial history before evaluating a specific study. See Shire's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hereditary Angioedema condition card totals 15 registered trials; most-linked intervention C1 esterase inhibitor [human] (C1INH-nf); top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.